Company intelligence / Profile preview

BinDeBio

Shenzhen, Guangdong Sheng, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

BinDeBio has multiple programs in development, with their Mesothelin CAR-T cell therapy and AS-1601 (targeting PD-1) both in Phase 2 clinical trials. Their Mesothelin CAR-T therapy is being tested for gastric cancer and pancreatic cancer.

Therapeutic areas: OncologyImmunology
Modalities: CAR-T cell therapiesTCR-T cellular immunotherapyNanobodyAntibodyBiological products
Industry: Biotech

Drug pipeline

5 assets

DR5 CAR-T

4 more assets in the full pipeline.

Request access →

Partnerships

EurekaBioChinese Academy of SciencesVarious hospitals nationwide

Beyond the preview

Go deeper on BinDeBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BinDeBio.

Explore the full profile